Amanta Healthcare
Other · 1 quarter tracked · source-linked performance and management context.
Latest revenue
₹75 Cr
financial record pending verification
Quarters tracked
1
source records in the directory
Delivery assessment
Unscored
No scored management commitments are present yet.
Call date
2026-02-10
latest available source date
Signal trajectory
1 actual quarterCurrent read
Unscored
No scored management commitments are present yet.
Latest source read
What changed this quarter?
Amanta Healthcare reported Q3 FY26 revenue of ₹75 crore (+9.8% YoY) and EBITDA of ₹15 crore (21% margin), with PAT of ₹5 crore (+8.1% YoY). Growth was driven by steady demand in its Sterport IV fluid containers (40% of revenue) and high-margin SVP exports (20% of revenue). Management guided for ₹400 crore revenue in FY27, driven by a doubling of Sterport capacity to ~12 crore bottles (₹120 crore incremental revenue) and a new SVP line (₹30 crore incremental). A 10.8 MW solar plant (commissioning Q1 FY27) is expected to save ₹9 crore annually. Risks include ramp-up delays in SVP exports due to regulatory approvals and potential working capital strain from inventory buildup during capacity commissioning.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹75 Cr
Source date
2026-02-10
Across the record
Quarter history.
History modules